NASDAQ:ENTX Entera Bio (ENTX) Stock Price, News & Analysis $3.01 -0.01 (-0.33%) As of 11:33 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Entera Bio Stock (NASDAQ:ENTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Entera Bio alerts:Sign Up Key Stats Today's Range$3.00▼$3.1050-Day Range$2.49▼$3.2552-Week Range$0.91▼$4.20Volume36,135 shsAverage Volume938,523 shsMarket Capitalization$524.16 millionP/E RatioN/ADividend YieldN/APrice Target$9.60Consensus RatingModerate Buy Company Overview Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel. It develops oral peptide therapies for conditions that have traditionally been treated with injectable medicines, with a focus on bone and endocrine disorders. The company’s development programs include EB613, an oral formulation of parathyroid hormone being studied for osteoporosis, and EB612, an oral parathyroid hormone candidate for hypoparathyroidism. Entera uses its proprietary oral-delivery technology to pursue the development of these therapies. Entera Bio’s work is focused on research and clinical development rather than marketing approved medicines. Its programs are intended to address unmet treatment needs in its target conditions.AI Generated. May Contain Errors. Read More Entera Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreENTX MarketRank™: 2.352043524415 of 5 starsEntera Bio scored higher than 47% of companies evaluated by MarketBeat, and ranked 588th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingEntera Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEntera Bio has a consensus price target of $9.60, representing about 218.9% upside from its current price of $3.01.Amount of Analyst CoverageEntera Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Entera Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Entera Bio are expected to grow in the coming year, from ($0.40) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entera Bio is -7.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entera Bio is -7.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntera Bio has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.22% of the float of Entera Bio has been sold short.Short Interest Ratio / Days to CoverEntera Bio has a short interest ratio ("days to cover") of 15.59, which indicates bearish sentiment.Change versus previous monthShort interest in Entera Bio has recently increased by 27.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntera Bio does not currently pay a dividend.Dividend GrowthEntera Bio does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment0.62 News SentimentEntera Bio has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Entera Bio this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ENTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Entera Bio insiders have not sold or bought any company stock.Percentage Held by Insiders3.72% of the stock of Entera Bio is held by insiders.Percentage Held by Institutions14.11% of the stock of Entera Bio is held by institutions.Read more about Entera Bio's insider trading history. Receive ENTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENTX Stock News HeadlinesEntera Bio Ltd. (NASDAQ:ENTX) Stock Has Average Target Price of $9.60November 13, 2026 | americanbankingnews.comEntera Bio Q3 Loss Widens; Expects Phase 3 Osteoporosis Topline Data In H2'28November 9, 2026 | rttnews.comMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.November 17 at 1:00 AM | Profits Run (Ad)Entera Bio Earnings & ForecastsNovember 8, 2026 | benzinga.comEntera Announces Third Quarter 2026 Financial Results and Business UpdatesNovember 6, 2026 | globenewswire.comEntera Bio (ENTX) Projected to Announce Quarterly Earnings on FridayNovember 6, 2026 | americanbankingnews.comEntera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of DirectorsOctober 27, 2026 | finance.yahoo.comEntera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and ...October 13, 2026 | markets.businessinsider.comSee More Headlines ENTX Stock Analysis - Frequently Asked Questions How have ENTX shares performed this year? Entera Bio's stock was trading at $1.94 at the beginning of the year. Since then, ENTX stock has increased by 55.2% and is now trading at $3.01. How were Entera Bio's earnings last quarter? Entera Bio Ltd. (NASDAQ:ENTX) issued its earnings results on Friday, November, 6th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by $0.05. When did Entera Bio IPO? Entera Bio (ENTX) raised $13 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00-$10.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager. Who are Entera Bio's major shareholders? Top institutional investors of Entera Bio include Nantahala Capital Management LLC (1.73%) and Marshall Wace LLP (0.12%). Insiders that own company stock include Miranda Jayne Toledano, Sean Ellis, Geno J Germano and Haya Taitel. View institutional ownership trends. How do I buy shares of Entera Bio? Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Entera Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entera Bio investors own include SNDL (SNDL), MARA (MARA), Ocugen (OCGN), NIO (NIO), Riot Platforms (RIOT), AMC Entertainment (AMC) and Bionano Genomics (BNGO). Company Calendar Last Earnings11/06/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ENTX's financial health is in the Green zone, according to TradeSmith. ENTX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ENTX CIK1638097 Webwww.enterabio.com Phone(722) 532-7151FaxN/AEmployees21Year Founded2010Price Target and Rating Average Price Target for Entera Bio$9.60 High Price Target$11.00 Low Price Target$9.00 Potential Upside/Downside+217.4%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.55% Return on Assets-36.15% Debt Debt-to-Equity RatioN/A Current Ratio128.41 Quick Ratio8.98 Sales & Book Value Annual Sales$40 thousand Price / Sales13,169.34 Cash FlowN/A Price / Cash FlowN/A Book Value$1.58 per share Price / Book1.91Miscellaneous Outstanding Shares174,140,000Free Float167,660,000Market Cap$526.77 million OptionableOptionable Beta1.48 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ENTX) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.